Clinical Trial Update: A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

Phase 3 trial of Rozanolixizumab in persistent or chronic primary immune thrombocytopenia was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: TERMINATED | Results posted: 2024-02-05